PSMA PET/CT scan has changed the current landscape of patients with PC, not only due to its impact on staging and localizing recurrences but also because it has been suggested as an essential tool for selecting patients with mCRPC who are eligible for radioligand therapy. This evidence concerns the gene FOLH1 and pachyonychia congenita.